There is indeed research on stem cell therapy for cerebral infarction in China, and search news can also find relevant reports.
Researchers from the Neurointerventional Department of the 208th Hospital of China People's Liberation Army published papers to observe the clinical efficacy and safety of autologous bone marrow mesenchymal stem cells (BMSCs) interventional transplantation in the treatment of cerebral infarction. It is pointed out that bone marrow mesenchymal stem cell transplantation can improve the symptoms of patients with cerebral infarction and improve their motor and cognitive functions to some extent, and autologous bone marrow stem cell transplantation is safe and effective.
120 patients with cerebral infarction were randomly divided into stem cell transplantation group and control group, with 60 cases in each group. The control group was given routine drug treatment, and the treatment group was given recombinant human granulocyte colony stimulating factor 150μg subcutaneous injection on the basis of routine drug treatment. After the routine white blood cell count rises to about 30× 109/L, 200 ml of autologous bone marrow can be extracted. Autologous bone marrow was treated with stem cell isolation kit to obtain mesenchymal stem cells. Autologous bone marrow mesenchymal stem cells are used for stem cell interventional transplantation, and mesenchymal stem cells are superselective to enter the blood supply artery of brain lesions. Before treatment, after treatment, 1 month and 6 months, the neurological function FIM was scored, and the motor and cognitive abilities were evaluated by the internationally accepted functional independence rating scale.
All patients with 120 entered the result analysis, and the scores of functional independence rating scale in transplantation group were significantly higher than those in control group at 1 and 6 months after treatment, and the difference between the two groups was statistically significant (P